Product Pathways - Growth Factors/Cytokines
Mouse Interleukin-6 (mIL-6) #5216
Recombinant mouse IL-6 (mIL-6) Phe25-Thr211 (Accession #NP_112445) was expressed in human 293 cells at Cell Signaling Technology.
Recombinant mIL-6 contains no "tags" and the nonglycosylated protein has a calculated MW of 21,734. DTT-reduced and non-reduced protein migrate as 31 kDa polypeptides. Lower mobility in SDS-PAGE is due to glycosylation. The expected amino-terminal FPTSQ of recombinant mIL-6 was verified by amino acid sequencing.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mIL-6. All lots are greater than 98% pure.
The bioactivity of recombinant mIL-6 was determined in a B9 cell proliferation assay. The ED50 of each lot is between 0.5 and 2 pg/ml.
The purity of recombinant mIL-6 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant mIL-6 and staining overnight with Coomassie Blue.
The proliferation of B9 cells treated with increasing concentrations of mIL-6 was assessed. After 48 hour treatment with mIL-6, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.
Western blot analysis of extracts from B9 cells, untreated or treated with increasing concentrations of mIL-6 for 10 minutes, using Phospho-Stat3 (Tyr705) (D3A7) XP® Rabbit mAb #9145 (upper) and Stat3 (79D7) Rabbit mAb #4904 (lower).
Less than 0.01 ng endotoxin/1 μg mIL-6.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg mIL-6. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
IL-6 is a potent inducer of the acute phase response and is produced by T cells, macrophages, fibroblasts, endothelial, and other cells (1,2). IL-6 induces proliferation and differentiation and acts on B cells, T cells, thymocytes, and others. IL-6 in concert with TGFβ is important for developing Th17 responses. IL-6 binds to IL-6Rα and through this association induces gp130 homodimerization (1). gp130 homodimerization triggers the Jak/Stat cascade and the SHP2/MAPK (Erk) cascade (1,3,4). IL-6 also forms a complex with an IL-6Rα splice variant that is non-membrane associated (3).The IL-6/soluble IL-6Rα complex can then activate the gp130 signaling pathway on cells that express gp130 but not IL-6Rα (3). IL-6, through increasing expression of proangiogenic VEGF, may contribute to metastatic breast cancer (5).
- Heinrich, P.C. et al. (1998) Biochem J 334 ( Pt 2), 297-314.
- Heinrich, P.C. et al. (1998) Z Ernahrungswiss 37 Suppl 1, 43-9.
- Jones, S.A. (2005) J Immunol 175, 3463-8.
- Jenkins, B.J. et al. (2004) Mol Cell Biol 24, 1453-63.
- Hong, D.S. et al. (2007) Cancer 110, 1911-28.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.